Outcomes after urgent thyroidectomy following rapid control of thyrotoxicosis in Graves’ disease are similar to those after elective surgery in well-controlled disease by Ali, A. et al.
This is a repository copy of Outcomes after urgent thyroidectomy following rapid control of 
thyrotoxicosis in Graves’ disease are similar to those after elective surgery in 
well-controlled disease.




Ali, A., Debono, M. and Balasubramanian, S.P. orcid.org/0000-0001-5953-2843 (2019) 
Outcomes after urgent thyroidectomy following rapid control of thyrotoxicosis in Graves’ 
disease are similar to those after elective surgery in well-controlled disease. World Journal 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
ORIGINAL SCIENTIFIC REPORT
Outcomes After Urgent Thyroidectomy Following Rapid Control
of Thyrotoxicosis in Graves’ Disease are Similar to Those After
Elective Surgery in Well-Controlled Disease
Adibah Ali1 • Miguel Debono2 • Sabapathy P. Balasubramanian1,3
Published online: 12 August 2019
 The Author(s) 2019
Abstract
Background Surgery for Graves’ disease (GD) is usually performed after adequate control with medical treatment.
Occasionally, rapid pre-operative optimization is required. The primary objective was to compare the outcomes of
patients undergoing elective surgery for well-controlled GD with those undergoing rapid pre-operative treatment. We
also propose a formal treatment protocol for future use.
Methods A retrospective cohort study in a tertiary referral centre included 247 patients with well-controlled GD
undergoing elective surgery and 19 patients with poorly controlled disease undergoing surgery after rapid opti-
mization. The latter group did not respond well to thionamides (carbimazole and/or propylthiouracil) or had intol-
erance or side effects to thionamides and were treated with a range of non-thionamide drugs, including Lugol’s
iodine, cholestyramine, beta blockers and steroids (with or without thionamides), and closely monitored for
1–2 weeks before surgery. Outcome measures included thyroid storm, hypoparathyroidism and recurrent laryngeal
nerve palsy.
Results In total, 266 patients with male-to-female ratio of 1:6 and median (interquartile range) age of 39 (31–51)
were included. Overall, long-term recurrent laryngeal palsy and hypoparathyroidism occurred in 1 (0.38%) and 13
(4.9%) patients, respectively. No patient had thyroid storm. There was no significant difference in hypoparathy-
roidism (p = 1), vocal cord palsy (p = 0.803) and post-operative bleeding (p = 0.362), between elective surgery and
rapid optimization groups.
Conclusion Rapid pre-operative treatment is effective, safe and is associated with similar outcomes compared to
usual treatment. A rapid pre-operative optimization protocol is proposed.
Introduction
Graves’ disease (GD) represents 50–80% of all patients
with hyperthyroidism [1]. It occurs more commonly in
women, with adjusted female-to-male ratio of 3.9:1 [2].
The main goal of treatment is to normalize thyroid
hormone levels and achieve remission. The three current
modalities for treatment of GD include anti-thyroid drugs
(ATD), radioiodine ablation (RIA) and surgery. ATD
treatment is the initial standard treatment, usually lasting
for between 6 and 18 months [3]. It induces remission in
over two-thirds of patients, of which over a third (36.7%)
relapse in the short to medium term [2]. Definitive
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treatment with either RIA or surgery is considered in
relapsed or uncontrolled GD. Surgery is preferred in
patients who are pregnant, unsuitable for RIA or those with
severe eye disease or large goitres [4]. The main compli-
cations of thyroid surgery are laryngeal nerve injury and
hypoparathyroidism (2–5%) [5]. Uncommon complications
include post-operative bleeding and infection.
The risk of perioperative thyroid storm is reduced by
adequate pre-operative optimization with appropriate
medical treatment [6]. Different strategies have been pro-
posed to facilitate this [7–9]. In patients with uncontrolled
disease and those who need urgent surgery, rapid pre-op-
erative preparation may be necessary. Panzer et al. [10]
demonstrated the effectiveness of a rapid preparation pro-
tocol (n = 17) with 500 mg iopanoic acid twice a day,
1 mg dexamethasone twice a day along with beta blockers
and thionamides over 7 days. This is similar to other
studies on the safety and effectiveness of regimens
including ATD in addition to either sodium iopodate or
iopanoic acid [7, 8] or combinations of steroids, iopanoic
acid and beta blockers [8, 9]. These studies appear to have
used a rigid protocol irrespective of the severity of thyro-
toxicosis and previous tolerance to ATD treatments. Most
studies did not have a control group [8, 9, 11] except one
which had a very small number of control patients under-
going surgery for well-controlled disease [7].
Surgery for GD is thought to be associated with an
increased risk of complications compared to other thyroid
conditions [12–14]. There is also a concern that patients
with poorly controlled disease have an increased risk of
complications [15], and post-operative hungry bone syn-
drome may compound the effects of post-operative
hypoparathyroidism [16].
The aim of this study is to describe the clinical outcomes
of patients undergoing urgent surgery for Graves’ disease
following rapid optimization and compare these to patients
undergoing elective surgery for well-controlled disease.
We also describe the effectiveness of treatment regimens
used in the latter group of patients and propose a formal
protocol for future use.
Methods
This is a retrospective cohort study of consecutive patients
who underwent surgery for GD in one unit over a 6-year
period (January 2010 to December 2016). Data on demo-
graphics, surgical and perioperative details, and clinical
outcomes were collected from electronic records and
recorded in an Excel spreadsheet.
Laryngoscopy, anaesthetic assessment, thyroid and cal-
cium biochemistry were routinely performed before sur-
gery. For the purpose of this study, patients with controlled
GD are those with normal or mildly elevated thyroid hor-
mone levels (FT4\ 30 pmol/L and FT3\ 10 pmol/L)
and clinically euthyroid with outpatient medical treatment
and underwent thyroidectomy as a planned elective pro-
cedure. The indication for surgery included one of the
following—relapsed Graves’ disease needing further
medical treatment, associated large goitre, significant thy-
roid eye disease or patient wish for definitive treatment [2].
These patients were usually on ATD (carbimazole or
propylthiouracil) either as sole treatment (dose titration
regimen) or on ATD and thyroxine (block and replace
regime). Most patients were prescribed Lugol’s iodine at
dose of 0.3 mL three times a day for 10 days before sur-
gery. Patients with poorly controlled GD and/or those who
required rapid optimization were either treated as frequent
outpatient visits or as inpatients for rapid control of thy-
rotoxicosis prior to surgery using a combination of differ-
ent drugs. These patients were either intolerant or
responded poorly to anti-thyroid drugs and needed urgent
definitive treatment (reasons included significant thyroid
eye disease, awaiting treatment for other medical condi-
tions or patient choice). These patients were defined as
having either FT4[ 30 pmol/L, FT3[ 10 pmol/L or had
thyroid hormone levels persistently above the normal range
with clinical features of hyperthyroidism (as judged by the
treating clinician). Treatment included a combination of
ATD, Lugol’s iodine, cholestyramine, beta blockers and
steroids, continued up to the day of surgery.
After surgery, patients were started on 1.6 mcg/kg of
thyroxine. Routine prophylactic calcium or vitamin D
supplements were not used. Vitamin D deficiency was
treated if detected—either before or immediately after
surgery. Post-operative hypocalcaemia and hypoparathy-
roidism were tested for and treated in accordance with a
standard protocol [17]. All patients were routinely offered
laryngoscopy after surgery. Outcomes assessed included
the occurrence of thyroid storm, temporary and long-term
hypocalcaemia and/or hypoparathyroidism, recurrent
laryngeal nerve injury, length of post-operative hospital
stay and readmission within 30 days of surgery. Thyroid
storm was defined as the occurrence of thyrotoxicosis and
at least one neurological manifestation and one of fever,
tachycardia, congestive heart failure, gastrointestinal or
hepatic features [18]. Temporary hypocalcaemia was
defined as adjusted calcium level below 2.1 mmol/L on the
first post-operative day. Patients were considered to have
long-term hypoparathyroidism if they required treatment
for over 6 months. Recurrent laryngeal nerve palsy was
identified at laryngoscopy, and patients were considered to
have long-term palsy if this lasted for over 6 months. The
reference ranges included 0.27–4.2 mIU/L for TSH,
12–22 pmol/L for FT4, 3.1–6.8 pmol/L for FT3,
2.1–2.6 mmol/L for calcium and 1.6–6.9 pmol/L for iPTH.
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The data were exported to SPSS for analysis. Data were
described as frequencies and/or percentages (for categori-
cal data); mean and standard deviation for continuous,
normally distributed data; and median (and interquartile
range) for continuous data that were not normally dis-
tributed. The Pearson Chi-square test with continuity cor-
rection or Fisher’s exact test was used to determine
associations and differences in categorical data sets. The
Student’s t test or the Mann–Whitney U test was used for
comparisons of continuous data depending on whether the
data were normally distributed or not. A significance value
of p\ 0.05 was used.
The study was registered with the R&D Department in
Sheffield Teaching Hospitals (STH 20132). As this was an
observational study, a formal ethics application and indi-
vidual patient consent were not deemed necessary. Patient
confidentiality and privacy was maintained during data
collection, and the data were anonymized before analysis
and reporting.
Results
Surgery was performed in 266 patients with a male-to-
female ratio of 1:6. The median (25th–75th centile) age at
surgery was 39 (31–51) years. Five (1.9%) patients had a
documented history of radioiodine ablation. All patients
(except one who underwent subtotal resection) underwent
total or near total thyroidectomy. Four consultants were
involved in either performing the surgery or supervising
trainees. Of 266 patients, 247 (92.9%) patients were well
controlled and had elective surgery. Nineteen (7.1%)
patients were considered to be poorly controlled in an
outpatient setting and/or required rapid optimization prior
to surgery. Of these, 14 were treated as inpatients while 5
patients were monitored daily as outpatient. Five (26%)
patients were intolerant to anti-thyroid drugs and were
managed with other agents. Figure 1 shows the treatment
regimens administered in the poorly controlled group. Five
patients required dose adjustments (3 patients required
increased PTU; 2 patients required increased propranolol).
Steroids were administered in 2 patients about 2–3 days
prior to surgery. Two patients were intolerant to
cholestyramine. The baseline characteristics of patients are
displayed in Table 1.
The median (25th–75th centile) FT4 and FT3 levels at
the time of listing for surgery were 40 (31–75) pmol/L and
15 (10–21) pmol/L, respectively, for the rapidly optimized
group. This was higher (Fig. 2) than the well-controlled
group [15 (12–18) pmol/L and 5 (4–6) pmol/L for FT4 and
FT3, respectively]. There was a downward trend in hor-
mone levels in all patients after commencing rapid treat-
ment (suppl. Figures 1 and 2). The majority of patients
demonstrated a reducing trend in FT4 levels within 3 days
after rapid treatment was initiated. Only 8 (42%) and 10
(53%) patients had normal free T4 and T3 levels, respec-
tively, prior to surgery as displayed in Table 2. Six patients
(32%) had both free T4 and T3 levels slightly elevated at
the time of surgery.
Parathyroid auto-transplantation was done on 9.8%
(n = 24) patients in the well-controlled group and none in
the poorly controlled group (p = 0.2, Fisher’s exact test).
At least one parathyroid gland was found on histology in
6.9% (n = 17) and 10.5% (n = 2) of the well- and poorly
controlled patients, respectively (p = 0.6, Fisher’s exact
test).
No patient in the cohort had thyroid storm. Sixty-six
(24.9%) patients had low post-op day 1 adjusted calcium;
62 (23.6%) required treatment for hypocalcaemia; and 13
(4.9%) had long-term hypoparathyroidism. There was no
significant difference in temporary or long-term
hypoparathyroidism rates and rates of reoperation for
bleeding between consultants. Eighteen (7%) patients had
post-operative vocal cord palsy and/or significant voice
Fig. 1 Management regimens
used in rapidly optimization of
poorly controlled Graves’
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change. Of these patients, only 1 had a documented per-
sistent cord palsy at 6 months. There was a statistically
significant difference in temporary vocal cord paresis (and/
or significant voice problems) between consultants
(p = 0.021; Fisher’s exact test), but not in long-term rates.
Six (2.3%) patients required surgery for post-operative
bleeding. One patient (in the rapidly pre-optimized group)
who underwent re-exploration for bleeding after thy-
roidectomy required admission to ICU for monitoring after
surgery, due to difficulty in intubation at the second
operation. The comparison of outcomes in the well- and
poorly controlled groups is shown in Table 3.
Discussion
This study demonstrates that outcomes following elective
surgery in well-controlled disease and urgent surgery after
rapid pre-operative optimization of thyroid function tests
are similar. Based on this experience, we have developed
and proposed a protocol to be used by clinicians when
managing uncontrolled patients with Graves’ disease prior
to surgery (Fig. 3).
The indications for surgery in GD vary between centres
in Europe, USA and worldwide [19, 20]. In the UK, the
majority of consultants preferred surgery over RIA for
relapsed Graves’ disease, especially in the presence of
thyroid eye disease and pregnancy [21]. Other indications
for surgery include suspected thyroid malignancy, large
thyroid nodule, coexisting primary hyperparathyroidism
and a contraindication for ATD and RIA [21–23].
Fig. 2 Pre-admission free T4 and free T3 levels in well-controlled, elective and rapidly optimized, urgent patients with Graves’ disease
Table 1 Comparison of baseline characteristics in well-controlled, elective versus rapidly optimized patients with Graves’ disease
Well-controlled, elective (%) Rapidly optimized, urgent (%) P value
M/F ratio 1:6.5 (n = 247) 1:18 (n = 19) 0.483*
Median age (25th–75th) 40 (30–51) 33 (23–38) 0.004**
History of RIA (n = 245) 5 (2) 0 (0) 1*
Consultants
A 77 (31) 2 (11) 0.115*
B 16 (6) 0 (0)
C 4 (2) 0 (0)
D 150 (61) 17 (89)
(n = 245) (n = 19)
Median duration of surgery (min) 191 (164–221) 201 (182–218) 0.355**
Median hospital stay after surgery (days) 1 (1–2) 2 (1–4) 0.065**
Bold value indicates significant results
*Fisher’s exact test
**Mann–Whitney U test
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However, temporary recurrent laryngeal nerve palsy and
permanent hypoparathyroidism are reported to be higher
after surgery for Graves’ compared to surgery for other
benign thyroid diseases (8.3% vs. 0% and 11.5% vs. 2.5%,
respectively) [14].
In this study, 4.9% (n = 13) had long-term
hypoparathyroidism and 1 patient had long-term nerve
palsy. This is comparable to a large national database study
which reported that 12.4% and 0.9% had hypoparathy-
roidism and vocal cord palsy, respectively [12]. However,
the hypoparathyroidism and unilateral vocal cord palsy
were not clearly defined in this report. In a meta-analysis
by Tapash et al. [24], permanent recurrent laryngeal nerve
injury occurred in 0.9% of TT patients and 0.7% of ST
patients, while permanent hypoparathyroidism occurred in
1.6% of TT patients and 1.0% of ST patients.
In the well-controlled, elective group, the surgery was
performed without rapid optimization in some patients who
had high free T3 levels prior to surgery because the patients
were euthyroid and free T4 levels were still in normal
range (Fig. 2).
In this series, the patients in the rapidly optimized group
are predominantly women and significantly younger com-
pared to the well-controlled group (median of 33 vs.
40 years, respectively, p = 0.004). Young age limits the
option of RIA as a number of young women are concerned
about pregnancy [25]. Furthermore, eye disease (com-
monly present in rapidly optimized GD) has a higher risk
of progression in patients treated with RIA compared to
surgery [26, 27]. In addition, Lugol’s iodine or iopodate
cannot be used in patients undergoing RIA. Therefore,
surgery following rapid optimization is often the preferred
treatment in many patients with poorly controlled disease.
Preparation for surgery in poorly controlled GD requires
close monitoring and dose adjustments. Although some
studies suggest that biochemical hyperthyroidism may not
increase morbidity [28, 29], these are retrospective studies
from high volume centres and may not be generalizable. It
is also not clear whether these patients had reducing free
T3 and T4 levels prior to surgery. Current guidelines from
the American Thyroid Association strongly recommend
that patients ‘should be rendered euthyroid prior to the
procedure’ [23].
Rendering patients euthyroid can be achieved by vary-
ing combinations of ATD and other drugs (ipodate, iodi-
nated radiographic contrast agent, dexamethasone,
B-blocker and cholestyramine). A comparative study had
described that the combination of 500 mg iopanoic acid
twice a day, 1 mg dexamethasone twice a day, beta blocker
and ATD rapidly reduced the T4 and T3 in majority of
patients (80%) to normal levels in 7 days [10]. In contrast,
although the majority of patients in our current study had
Table 2 Comparison of hormonal levels before and after rapid
optimization prior to surgery in poorly controlled GD
Patients FT4 (pmol/L) FT3 (pmol/L) TSH (mIU/L)
Before After Before After Before After
1 [ 100 30.2 35.2 6.7 \ 0.02 NA
2 24.5 12.8 7.1 3.3 \ 0.02 \ 0.02
3 24.3 8.3 23.9 7 \ 0.02 \ 0.02
4 36.4 29.6 15.7 8.5 \ 0.02 \ 0.02
5 37.5 29.4 11.5 8 \ 0.02 NA
6 [ 100 47.8 10.3 7.6 0.03 0.87
7 62.6 25.6 37.4 5.8 \ 0.02 \ 0.02
8 61 29.1 28.2 8.6 \ 0.02 \ 0.02
9 79 26.4 17.4 4.8 \ 0.02 \ 0.02
10 91.5 32.5 [ 50 11.4 \ 0.02 \ 0.02
11 91.8 21.2 39.7 6.9 \ 0.02 \ 0.02
12 [ 100 22.5 [ 50 8.6 \ 0.02 \ 0.02
13 27.1 14.7 10.3 4.4 \ 0.02 \ 0.02
14 30.9 11.6 9.7 2.6 NA NA
15 42.5 11.6 15.5 2.6 \ 0.02 \ 0.02
16 [ 100 18.3 34.4 6.4 \ 0.02 \ 0.02
17 22.3 16.6 4 3 \ 0.03 \ 0.03
18 31.5 21.9 11.8 5.9 \ 0.03 \ 0.01
19 27.6 15.1 12.8 4.8 \ 0.03 \ 0.03
Table 3 Comparison of clinical outcomes between well-controlled, elective versus rapidly optimized patients with Graves’ disease
Well-controlled, elective (%) Rapidly optimized, urgent (%) P value*
Low ‘adjusted serum calcium’ on day after surgery 62/246 (25.2) 4/19 (21.1) 0.790
Post-op hypocalcaemia needing treatment 57/243 (23.5) 5/19 (26.3) 0.781
Long-term (6 months) hypoparathyroidism 12/244 (4.9) 1/19 (5.3) 1
Post-op cord palsy and/or significant voice problem 18/238 (7.6) 0/18 (0) 0.624
6-month cord check 1/241 (0.4) 0/19 (0) 0.803
Post-operative bleeding 5/247 (2) 1/19 (5.3) 0.362
*Fisher’s exact test
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showed a declining trend in hormone levels 3 days after
initiating the treatment, only 9 (47.3%) patients had
achieved normal levels prior to surgery. The rates of
temporary and long-term hypoparathyroidism were 3
(33.3%) and 1 (11.1%), respectively, in the 9 patients with
normal thyroid hormone levels versus 1 (10%) and none,
respectively, in the other 10 patients. No patient in the
rapidly optimized group had documented evidence of sig-
nificant voice change or post-operative vocal cord palsy
and long-term recurrent laryngeal nerve damage. The
number of patients who had achieved normal thyroid hor-
mone levels pre-operatively was lower than that described
in previous studies. This is likely due to higher baseline T4
and T3 in our patients (Table 2). Based on this, we suggest
that a normal level need not be achieved as long as the
levels are declining prior to surgery and the patients are
clinically euthyroid.
In this series, the protocol for rapid optimization of
poorly controlled group includes 0.3 mLs Lugol’s iodine
three times a day in all patients at least 10 days prior to
surgery and ATD if they have been tolerated. Cholestyra-
mine, beta blockers and dexamethasone were added
depending on patients’ clinical response to initial
medications. The effectiveness of protocols using different
combinations such as those used in this study has not yet
been reported in the literature.
This study is limited by its retrospective nature and
some missing outcome data. Two patients in the ‘poorly
controlled’ group did not have severe biochemical hyper-
thyroidism, but were judged by the treating clinician to
merit ‘rapid optimization’ and close monitoring. They were
therefore considered to be in the ‘poorly controlled’ group.
A number of patient-related (such as age, gender and
comorbidity) and treatment-related variables (such as
individual surgeon, trainee or surgeon performed, cumu-
lative experience over time) may have influenced outcomes
and were not adjusted for in multivariable analyses. The
numbers in the second group were limited, and this reduces
the power and increases the type II error rate of some of the
statistical analyses comparing the outcomes in the two
groups. There is a concern that ‘hungry bone syndrome’
may be a significant contributor to post-operative
hypocalcaemia. In the absence of biochemical parameters
including magnesium, phosphate and alkaline phosphate
measurements after surgery, we are unable to distinguish
clearly between hungry bone syndrome and
Fig. 3 Proposed protocol for the rapid optimization of thyroid function prior to surgery in poorly controlled Graves’ disease. Notes The
proposed starting doses of the medications are Lugol’s iodine at 0.3 mL tds, propranolol 20 mg tds, cholestyramine 4 g tds and
dexamethasone 1 mg bd. The dose of propranolol may be increased up to 80 mg tds and that of dexamethasone to 2 mg bd. For patients on
cholestyramine, no other medications should be administered at least 2 h before and 4 h after cholestyramine
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hypoparathyroidism as causes of post-operative hypocal-
caemia. However, within the constraints of the analysis
presented, the observation of similar rates of ‘low calcium’
on the day after surgery argues against a significant impact
of hungry bone syndrome in the rapidly optimized cohort
of patients.
However, this study still provides evidence that rapid
pre-optimization in poorly controlled GD and urgent sur-
gery are effective and safe. The protocol for pre-operative
optimization was left to the discretion of the treating
clinicians. Based on this experience and following dis-
cussion of these results in a multi-disciplinary team, we
have formulated a protocol for pre-operative rapid prepa-
ration in patients with Graves’ disease who have not been
adequately controlled in an elective, outpatient setting or
those who need urgent surgical treatment of Graves’ dis-
ease (such as those needing urgent treatment of other newly
diagnosed conditions). In this protocol (Fig. 3), rapid
preparation is started at least 10 days prior to the proposed
operation with the objective of ensuring that the patient is
clinically euthyroid and has free T4 levels of\ 30 pmol/L
and free T3 levels of\ 10 pmol/L on the day of surgery.
All patients are advised to continue their current anti-thy-
roid medications and commence Lugol’s iodine (0.3 mL
tds) and propranolol (20 mg tds) 10 days prior to surgery.
The biochemistry is monitored very closely as illustrated in
Fig. 3 and further drugs (such as cholestyramine and dex-
amethasone) are added or the dose of medications are
adjusted in accordance with the biochemical results. Other
drugs such as lithium [30] and therapeutic plasmapheresis
[31] have been reported as being effective in the rapid
control of thyrotoxicosis prior to ablative treatment, but the
authors do not have any experience of these modalities.
In summary, the rapid pre-operative treatment of
patients with poorly controlled Graves’ disease is effective,
safe and there is no significant difference in morbidity
compared to usual treatment.
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